» Articles » PMID: 20075570

Effect of Fenofibrate on Uric Acid Metabolism and Urate Transporter 1

Overview
Journal Intern Med
Specialty General Medicine
Date 2010 Jan 16
PMID 20075570
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To examine the effects of fenofibrate, an antilipotropic drug, on uric acid metabolism in healthy male subjects and on urate transporter 1 (URAT1).

Methods: Fenofibrate was administered to nine male volunteers at a dose of 300 mg (corresponding to 200 mg of micronized fenofibrate), and the metabolic parameters of uric acid were investigated for more than 12 hours. In addition, the effect of fenofibrate on URAT1-expressing cells was examined.

Results: After the administration of fenofibrate, the concentration of serum uric acid had significantly decreased from 5.8+/-0.4 mg/dL to 4.3+/-0.3 mg/dL at 10 h. Uric acid clearance and the fractional excretion of uric acid increased. Fenofibric acid, a fenofibrate metabolite, inhibited URAT1 to an extent similar to that observed with benzbromarone and losartan.

Conclusion: Fenofibrate decreased serum uric acid levels by increasing its urinary excretion, most likely through the inhibition of URAT1 by fenofibric acid, its major metabolite.

Citing Articles

Hyperuricemia prevalence and its risk factors in uremic patients undergoing maintenance hemodialysis.

Zhang M, Huang G, Bao X, Yang Q BMC Nephrol. 2025; 26(1):46.

PMID: 39885381 PMC: 11780984. DOI: 10.1186/s12882-025-03978-8.


Mechanism and use strategy of uric acid-lowering drugs on coronary heart disease.

Cai R, Li F, Li Y, Li Y, Peng W, Zhao M Int J Cardiol Heart Vasc. 2024; 53:101434.

PMID: 38974459 PMC: 11225710. DOI: 10.1016/j.ijcha.2024.101434.


Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease.

Fuior E, Zvintzou E, Filippatos T, Giannatou K, Mparnia V, Simionescu M Biomedicines. 2023; 11(10).

PMID: 37893070 PMC: 10604751. DOI: 10.3390/biomedicines11102696.


Biodegradation of Inosine and Guanosine by YD01.

Du X, Jiang Y, Sun Y, Cao X, Zhang Y, Xu Q Int J Mol Sci. 2023; 24(19).

PMID: 37833910 PMC: 10573016. DOI: 10.3390/ijms241914462.


Prevalence and associated factors of hyperuricemia among Chinese patients with diabetes: a cross-sectional study.

Sun S, Chen L, Chen D, Li Y, Liu G, Ma L Ther Adv Endocrinol Metab. 2023; 14:20420188231198620.

PMID: 37719790 PMC: 10501065. DOI: 10.1177/20420188231198620.